Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· May 17, 2026

Bond Traders See Tipping Point Toward New Era of Higher Yields

View original at finance.yahoo.com
Bond Traders See Tipping Point Toward New Era of Higher Yields (Bloomberg) -- A new era of elevated borrowing costs is potentially underway as war-driven inflation angst intensifies in the US bond market, sending 30-year yields toward a two-decade high above 5%…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Traders now see a Federal Reserve interest-rate hike as a lock by March, a dramatic reversal from late February 2026 when two quarter-point cuts were expected for the year.

    60% confidence
  • Price action is concerning for two reasons: long-end rates are rising globally which tend to feed on each other, and the prospect of Fed hikes is coming into the market narrative.

    60% confidence
  • Higher yields on long-term Treasuries, a benchmark for mortgage rates and corporate loans, are likely to reignite talk of growth risks from elevated oil prices.

    60% confidence
  • The Iran war has flipped the bond-market narrative on its head since late February, when two quarter-point cuts were expected for 2026.

    60% confidence
  • The interest rate range has moved higher and will remain elevated unless the Strait of Hormuz is opened.

    60% confidence
  • The primary worry is that expectations for hotter inflation are taking hold, which adds pressure on incoming Fed Chair Kevin Warsh and spoils bets that he will deliver rate cuts soon after taking the helm.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com